Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 7, Issue 2, 2009

The constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) are activated by a variety of endogenous and exogenous ligands, such as steroid hormones, bile acids, pharmaceuticals, and environmental, dietary, and occupational chemicals. In turn, they induce phase I-III detoxification enzymes and transporters that help eliminate these chemicals. Because many of the chemicals that activate CAR and PXR Read More

With parallel advances in genomics and in nutrition research, a new hybrid science has emerged at their intersection, often referred to as nutritional genomics which includes nutrigenomics and nutrigenetics. While the operational definitions will continue to evolve as nutritional genomics matures as a new field of inquiry, a central tenet will likely be on ways in which the human genome interacts with nutritional e Read More

Variations in both the genome and epigenome can affect individual nutrient requirements. In order to optimise nutrient intake for good health, it becomes important to understand the way in which nutrients affect the expression of key genes. Epigenetic events imply a change of gene expression without a heritable change in DNA base pairs. These events may result from the action of transcription factors, the methylati Read More

Over the last decade there has been vast interest in and focus on the implementation of personalized genomic medicine. Although there is general agreement that personalized genomic medicine involves utilizing genome technology to assess individual risk and ensure the delivery of the “right treatment for the right patient at the right time,”different categories of stakeholders focus on different aspects of personalized genomic Read More

Lung cancer is the fourth most frequently diagnosed human malignancy and the most common cause of cancerrelated deaths in the western world. Consideration of human genetic variation in the post-genomics era increased the rate of discovery of novel therapeutic targets that could become the mainstay of personalized anti-cancer treatment. These targets include tumour suppressor genes such as tumour protein (T Read More